A tumor-infiltrating lymphocyte from a melanoma metastasis with decreased expression of melanoma differentiation antigens recognizes MAGE-12

Journal of Immunology

Volumn 164, Issue 8, 2000, Pages 4382-4392

  Panelli, Monica C ^a   Bettinotti, Maria P ^b   Lally, Kate ^b   Ohnmacht, Galen A ^a   Li, Yong ^a   Robbins, Paul ^a   Riker, Adam ^a   Rosenberg, Steven A ^a   Marincola, Francesco M ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; COMPLEMENTARY DNA; CYTOKINE; HLA ANTIGEN CLASS 1; HLA B ANTIGEN; MELANOMA ANTIGEN; MESSENGER RNA; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOLOGY; GENE EXPRESSION; HLA TYPING; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE; VACCINATION;

EID: 0034655180     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.164.8.4382     Document Type: Article

References (63)

1. Rosenberg, S. A. 1997. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol. Today 18:175.
2. Kawakami, Y., S. Eliyahu, C. H. Delgado, P. F. Robbins, L. Rivoltini, S. L. Topalian, T. Miki, and S. A. Rosenberg. 1994. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA 91:3515.
3. Kawakami, Y., S. Eliyahu, K. Sakaguchi, P. F. Robbins, L. Rivoltini, J. R. Yannelli, E. Appella, and S. A. Rosenberg. 1994. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor-infiltrating lymphocytes. J. Exp. Med. 180:347.
4. Coulie, P. G., V. Brichard, A. Van Pel, T. Wolfel, J. Schneider, C. Traversari, S. Mattei, E. De Plaen, C. Lurquin, J. P. Szikora, et al. 1994. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 180:35.
5. Kawakami, Y., S. Eliyahu, C. H. Delgado, P. F. Robbins, K. Sakaguchi, E. Appella, J. R. Yannelli, G. J. Adema, T. Miki, and S. A. Rosenberg. 1994. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. USA 91:6458.
6. Rosenberg, S. A., B. S. Packard, P. M. Aebersold, D. Solomon, S. L. Topalian, S. T. Toy, P. Simon, M. T. Lotze, J. C. Yang, C. A. Seipp, et al. 1988. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma: a preliminary report. N. Engl. J. Med. 319:1676.
7. Kawakami, Y., S. Eliyahu, C. Jennings, K. Sakaguchi, X. Kang, S. Southwood, P. F. Robbins, A. Sette, E. Appella, and S. A. Rosenberg. 1995. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J. Immunol. 154:3961.
8. Rosenberg, S. A., and D. E. White. 1996. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J. Immunother. 19:81.
9. Marincola, F. M., E. M. Jaffe, D. J. Hicklin, and S. Ferrone. 2000. Escape of human solid tumors from T cell recognition: molecular mechanisms and functional significance. Adv. Immunol. 74:181.
10. de Vries, T. J., A. Fourkour, T. Wobbes, G. Verkroost, D. J. Ruiter, and G. N. van Muijen. 1997. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions. Cancer Res. 57:3223.
11. Scheibenbogen, C., I. Weyers, D. Ruiter, M. Willhauck, A. Bittinger, and U. Keilholz. 1996. Expression of gp100 in melanoma metastases resected before or after treatment with IFN-α and 1L-2. J. Immunother. 19:375.
12. Cormier, J. N., Y. M. Hijazi, A. Abati, P. Fetsch, M. Bettinotti, S. M. Steinberg, S. A. Rosenberg, and F. M. Marincola. 1998. Heterogeneous expression of melanoma-associated antigens (MAA) and HLA-A2 in metastatic melanoma in vivo. Int. J. Cancer 75:517.
13. Riker, A., U. S. Kammula, M. C. Panelli, E. Wang, A. Abati, P. Fetsch, K.-H. Lee, S. M. Steinberg, S. A. Rosenberg, and F. M. Marincola. 1999. Immune selection following antigen specific immunotherapy of melanoma. Surgery 126: 112.
14. Driscoll, M. C., A. Chu, and M. W. Hilgartner. 1996. Heteroduplex analysis in hemophilia B: detection of two novel factor IX gene mutations. Am. J. Hematol. 51:324.
15. Coulie, P. G., B. J. van den Eynde, P. van der Bruggen, A. Van Pel, and T. Boon. 1997. Antigens recognized by T-lymphocytes on human tumours. Biochem. Soc. Trans. 25:544.
16. Takahashi, K., S. Shichijo, M. Noguchi, M. Hirohata, and K. Itoh. 1995. Identification of MAGE-1 and MAGE-4 proteins in spermatogonia and primary spermatocytes of testis. Cancer Res. 55:3478.
17. Haas, G. G., O. J. D'Cruz, and L. E. De Bault. 1988. Distribution of human leukocyte antigen-ABC and -D/DR antigens in the unfixed juman testis. Am. J. Reprod. Immunol. 18:47.
18. DePlaen, E., K. Arden, C. Raversari, J. J. Gaforio, J. P. Szikora, C. De Smet, F. Brasseur, P. van der Bruggen, B. Lethe, C. Lurquin, et al. 1994. Structure, chromosomal localization and expression of 12 genes of the MAGE family. Immunoginetics 40:360.
19. De Smet, C., O. De Backer, I. Faraoni, C. Lurquin, F. Brasseur, and T. Boon. 1996. The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc. Natl. Acid. Sci. USA 93:7149.
20. Liteplo, R. G., and R. S. Kerbel. 1987. Reduced levels of DNA 5-methylcytosine in metastatic variants of the human melanoma cell line MeWo. Cancer Res. 47:2264.
21. Boon, T., P. G. Coulie, and B. Van den Eynde. 1997. Tumor antigens recognized by T cells. Immunol. Today 18:267.
22. Marchand, M., P. Weynants, E. Rankin, F. Arienti, F. Belli, G. Parmiani, N. Cascinelli, A. Bourlond, R. Vanwijck, and Y. Humblet. 1995. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int. J. Cancer 63:883.
23. Marchand, M., N. van Baren, P. Weynants, V. Brichard, B. Dreno, M. H. Tessier, E. Rankin, G. Parmiani, F. Arienti, Y. Humblet, et al. 1999. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int. J. Cancer 80:219.
24. Salgaller, M. L., J. S. Weber, S. Koenig, J. R. Yannelli, and S. A. Rosenberg. 1994. Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide. Cancer Immunol. Immunother. 39:105.
25. Toso, J. F., C. Oei, F. Oshidari, J. Tartaglia, E. Paoletti, H. K. Lyerly, S. Talib, and K. J. Weinhold. 1996. MAGE-1 specific precursor cytotoxic T-lymphocytes present among tumor-infiltrating lymphocytes from a patient with breast cancer: characterization and antigen specific activation. Cancer Res. 56:16.
26. Zorn, E., and T. Hercend. 1999. A MAGE-6-encoded peptide is recognized by expanded lymphocytes infiltrating a spontaneously regressing human primary melanoma lesion. Eur. J. Immunol. 29:602.
27. Kawakami, Y., and S. A. Rosenberg. 1996. T-cell recognition of self peptides as tumor rejection antigens. Immunol. Res. 15:179.
28. Fuchs, E. J., and P. Matzinger. 1996. Is cancer dangerous to the immune system? Semin. Immunol. 8:271.
29. Matzinger, P. 1998. An innate sense of danger. Semin. Immunol. 10:399.
30. Speiser, D. E., R. Miranda, A. Zakarian, M. F. Bachmann, K. McKall-Faienza, B. Odermatt, D. Hanahan, R. M. Zinkernagel, and P. S. Ohashi. 1997. Self antigens expressed by solid tumors Do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J. Exp. Med. 186:645.
31. Ochsenbein, A. F., P. Klenerman, U. Karrer, B. Ludewig, M. Pericin, H. Hengartner, and R. M. Zinkernagel. 1999. Immune surveillance against a solid tumor fails because of immunological ignorance. Proc. Natl. Acad. Sci. USA 96:2233.
32. Wang, Z., F. M. Marincola, L. Rivoltini, G. Parmiani, and S. Ferrone. 1999. Selective human leukocyte antigen (HLA)-A2 loss caused by aberrant pre-mRNA splicing in 624 MEL28 melanoma cells. J. Exp. Med. 190:205.
33. Cormier, J. N., M. C. Panelli, J. A. Hackett, M. Bettinotti, A. Mixon, J. Wunderlich, L. Parker, N. P. Restifo, S. Ferrone, and F. M. Marincola. 1999. Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an in vitro melanoma model. Int. J. Cancer 80:781.
34. Riker, A., M. C. Panelli, U. S. Kammula, E. Wang, J. Wunderlich, A. Abati, P. A. Fetsch, S. A. Rosenberg, and F. M. Marincola. 1999. Development and characterization of melanoma cell lines established by fine needle aspiration biopsy: advances in the monitoring of patients with metastatic melanoma. Cancer Detect. Prev. 23:387.
35. Moss, D. J., I. S. Misko, S. R. Burrows, K. Burman, R. McCarthy, and T. B. Sculley. 1988. Cytotoxic T-cell clones discriminate between A-and B-type Epstein-Barr virus transformants. Nature 331:719.
36. Wei, M. L., and P. Cresswell. 1992. HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides. Nature 356:443.
37. Marincola, F. M., P. Shamamian, R. B. Alexander, J. R. Gnarra, R. L. Turetskaya, S. A. Nedospasov, T. B. Simonis, J. K. Taubenberger, J. Yannelli, A. Mixon, et al. 1994. Loss of HLA haplotype and B locus down-regulation in melanoma cell lines. J. Immunol. 153:1225.
38. Lee, K.-H., M. C. Panelli, C. J. Kim, A. Riker, M. Roden, P. A. Fetsch, A. Abati, M. P. Bettinotti, S. A. Rosenberg, and F. M. Marincola. 1998. Functional dissociation between local and systemic immunse response following peptide vaccination. J. Immunol. 161:4183.
39. Berger, A. E., J. E. Davis, and P. Cresswell. 1982. Monoclonal antibody to HLA-A3. Hybridoma 1:87.
40. Radka, S. F., D. D. Kostyu, and D. B. Amos. 1982. A monoclonal antibody directed against the HLA-Bw6 epitope. J. Immunol. 128:2804.
41. Kruse, N., M. Pette, K. Toyka, and P. Rieckmann. 1997. Quantification of cytokine mRNA expression by RT PCR in samples of previously frozen blood. J. Immunol. Methods 210:195.
42. Riker, A., U. S. Kammula, M. C. Panelli, E. Wang, G. A. Ohnmacht, S. M. Steinberg, S. A. Rosenberg, and F. M. Marincola. 2000. Threshold levels of gene expression of the melanoma antigen gp100 correlate with tumor cell recognition by cytotoxic T-lymphocytes. Int. J. Cancer. In press.
43. Player, M. A., K. C. Barracchini, T. B. Simonis, L. Rivoltini, F. Arienti, C. Castelli, A. Mazzocchi, F. Belli, and F.M. Marincola. 1996. Differences in frequency distribution of HLA-A2 sub-types between American and Italian Caucasian melanoma patients: relevance for epitope specific vaccination protocols. J. Immunother. 19:357.
44. Dawkins, R. L., M. P. Degli-Esposti, L. J. Abraham, W. Zhang, and F. T. Christiansen. 1991. Conservation versus polymorphism of the MHC in relation to transplantation, immune responses and autoimmune disease. In Molecula Evolution of the Major Histocompatibility Complex, 1st Ed. J. Klein and D. Klein, eds. Springer-Verlag, Berlin, p. 391.
45. Falk, K., O. Rotzschke, B. Grahovac, D. J. Schendel, S. Stevanovic, V. Gnau, G. Jung, J. L. Strominger, and H. G. Rammensee. 1993. Allele-specific peptide ligand motifs of HLA-C molecules. Proc. Natl. Acad. Sci. USA 90:12005.
46. Serrano, A., B. Lethe, J. M. Delroisse, C. Lurquin, E. DePlaen, F. Brasseur, D. Rimoldi, and T. Boon. 1999. Quantitative evaluation of the expression of MAGE genes in tumors by limiting dilution of cDNA libraries. Int. J. Cancer 83:664.
47. Fetsch, P. A., F. M. Marincola, and A. Abati. 1999. The new melanoma markers MART-1 and Melan A: the NIH experience. Am. J. Surg. Pathol. 23:607.
48. Marincola, F. M., Y. M. Hijazi, P. Fetsch, M. L. Salgaller, L. Rivoltini, J. N. Cormier, T. B. Simonis, P. H. Duray, M. Herlyn, Y. Kawakami, and S. A. Rosenberg. 1996. Analysis of expression of the melanoma associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions. J. Immunother. 19:192.
49. Kammula, U. S., K.-H. Lee, A. Riker, E. Wang, G. A. Ohnmacht, S. A. Rosenberg, and F. M. Marincola. 1999. Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens. J. Immunol. 163:6867.
50. Panelli, M. C., A. Riker, U. S. Kammula, K.-H. Lee, E. Wang, S. A. Rosenberg, and F. M. Marincola. 2000. Expansion of tumor/T cell pairs from fine needle aspirates (FNA) of melanoma metastases. J. Immunol. 164:495.
51. Kawakami, Y., P. F. Robbins, X. Wang, J. P. Tupesis, M. R. Parkhurst, X. Kang, K. Sakaguchi, E. Appella, and S. A. Rosenberg. 1998. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating lymphocytes restricted by HLA-A1, -A2, and -A3 alleles. J. Immunol. 161:6985.
52. Zemmour, J., and P. Parham. 1992. Distinctive polymorphism at the HLA-C locus: implications for the expression of HLA-C. J. Exp. Med. 176:937.
53. Loftus, D., C. Castelli, T. M. Clay, P. Squarcina, F. M. Marincola, M. I. Nishimura, G. Parmiani, E. Appella, and L. Rivoltini. 1996. Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35). J. Exp. Med. 184:647.
54. Bettinotti, M., C. J. Kim, K.-H. Lee, M. Roden, J. N. Cormier, M. C. Panelli, K. C. Parker, and F. M. Marincola. 1998. Stringent allele/epitope requirements for MART-1/Melan A immunodominance: implications for peptide-based immunotherapy. J. Immunol. 161:877.
55. Marincola, F. M., P. Shamamian, T. B. Simonis, A. Abali, J. Hackett, T. O'Dea, P. Fetsch, J. Yannelli, N. P. Restifo, J. J. Mule, et al. 1994. Locus-specific analysis of human leukocyte antigen class I expression in melanoma cell lines. J. Immunother. 16:13.
56. Lethe, B., P. van der Bruggen, F. Brasseur, and T. Boon. 1997. MAGE-1 expression threshold for the lysis of melanoma cell lines by a specific cytotoxic T lymphocyte. Melanoma Res. 7(Suppl. 2):S83.
57. Nicotra, M. R., P. Nistico, A. Mangoni, F. Di Filippo, F. M. Marincola, and P. G. Natali. 1997. Melan-A/MART-1 antigen expression in cutaneous and ocular melanomas. J. Immunother. 20:466.
58. Boon, T., and S. Lucas. 1996. Antigenes de rejet des tumeurs et immunotherapie specifique du cancer. Bull Mem. Acad. R. Med. Belg. 151:469.
59. Rosenberg, S. A., J. C. Yang, D. Schwartzentruber, P. Hwu, F. M. Marincola, S. L. Topalian, N. P. Restifo, E. Dufour, L. Schwartzberg, P. Spiess, et al. 1998. Immunologic and therapeutic evaluation of a synthetic tumor associated peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4:321.
60. van der Bruggen, P., J. P. Szikora, P. Boel, C. Wildmann, M. Somville, M. Sensi, and T. Boon. 1994. Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw* 1601. Eur. J. Immunol. 24: 2134.
61. Van den Eynde, B., O. Peeters, O. De Backer, B. Gaugler, S. Lucas, and T. Boon. 1995. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J. Exp. Med. 182:689.
62. Rivoltini, L., D. J. Loftus, K. Barracchini, F. Arienti, A. Mazzocchi, W. E. Biddison, M. L. Salgaller, E. Appella, G. Parmiani, and F. M. Marincola. 1996. Binding and presentation of peptides derived from melanoma antigens MART-1 and gp100 by HLA-A2 subtypes: implications for peptide-based immunotherapy. J. Immunol. 156:3882.
63. Kim, C. J., D. R. Parkinson, and F. M. Marincola. 1997. Immunodominance across the HLA polymorphism: implications for cancer immunotherapy. J. Immunother. 21:1.